Trastuzumab (US brand name: Herceptin®) is a humanized monoclonal antibody IgG1 directed against the human epidermal growth factor receptor 2 (HER2) and is approved for the treatment of HER2-positive breast cancer and HER2-positive metastatic adenocarcinomas of the stomach or gastroesophageal junction (GEJ).
Antibodies, also known as immunoglobulins, are large protein molecules produced by the body’s immune system in response to antigenic stimuli that are either infectious agents, such as a bacteria, fungi, viruses, or parasites, or other molecular components recognized by the body’s immune system as foreign. Antibodies consist of two identical pairs of polypeptide chains, comprised of a heavy chain and a...
KeywordsBreast Cancer International Research Group Trastuzumab Cardiotoxicity
- Dokmanovic M, Wu WJ (2011) Trastuzumab: resistance and breast cancer. In: Gunduz M, Gunduz E (eds) Breast cancer: carcinogenesis, cell growth and signaling pathways. InTech, Rijeka, pp 171–204Google Scholar